Captor Therapeutics SA (CTX) AI Stock Analysis

• Market Cap: €215.07M
• Dividend Yield: N/A
• Average Volume (3M): 8.17K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.22
• Revenue Growth: -40.45%
• EPS Growth: 27.53%
• Country: PL
• Employees: 105
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 5,528,709
• 10 Day Avg. Volume: 14,659
• 30 Day Avg. Volume: 8,168
• PEG Ratio: 0.11
• Price to Book (P/B): 3.06
• Price to Sales (P/S): 12.45
• P/FCF Ratio: -6.15
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €37.05
• Price Target Upside: -2.50% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 44 Neutral
• Price Target: zł37.00 ▼(-2.63% Downside)

Captor Therapeutics SA's overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and negative cash flows. Technical analysis provides a neutral outlook, while valuation concerns arise due to the negative P/E ratio. The lack of earnings call and corporate events data limits additional insights.

Captor Therapeutics SA Business Overview & Revenue Model

Company Description

Captor Therapeutics SA (CTX) is a biopharmaceutical company focused on developing innovative therapeutics in the field of oncology and autoimmune diseases. Utilizing its proprietary Targeted Protein Degradation (TPD) platform, the company aims to create novel therapies that selectively degrade disease-causing proteins, thereby addressing unmet medical needs. Captor Therapeutics operates primarily in the biotechnology sector, with a pipeline that includes several preclinical and clinical-stage compounds designed to revolutionize treatment paradigms in cancer and other serious conditions.

How the Company Makes Money

Captor Therapeutics generates revenue primarily through strategic partnerships and collaborations with pharmaceutical companies, which provide funding for research and development efforts. These partnerships often include upfront payments, milestone payments tied to the achievement of specific clinical or regulatory goals, and royalties on future product sales. Additionally, the company may engage in licensing agreements that allow other firms to utilize its proprietary TPD technology, further diversifying its revenue streams. As the company advances its drug candidates through clinical trials, potential licensing deals and collaborations can significantly enhance its earnings potential.

Captor Therapeutics SA Financial Statement Overview

Summary

Captor Therapeutics SA faces significant financial challenges, with declining revenues, persistent losses, and negative cash flows. Despite low leverage, the inability to generate positive returns and cash flows raises concerns about its financial health and sustainability.

Income Statement

Captor Therapeutics SA has shown a declining revenue growth rate, with a significant drop of 18.24% in the latest year. The company is struggling with profitability, as evidenced by negative net profit margins and EBIT margins over the years. Despite some improvement in gross profit margins, the overall financial performance in terms of income is weak, reflecting challenges in achieving sustainable revenue growth and profitability.

Balance Sheet

The company's balance sheet shows a relatively low debt-to-equity ratio, indicating conservative leverage. However, the return on equity is negative, suggesting inefficiencies in generating returns from shareholders' equity. The equity ratio is moderate, but the overall financial stability is compromised by persistent losses and declining equity levels.

Cash Flow

Captor Therapeutics SA has experienced negative free cash flow growth, indicating challenges in generating cash from operations. The operating cash flow to net income ratio is negative, reflecting cash flow issues. Although the free cash flow to net income ratio is slightly above 1, the overall cash flow situation is concerning, with consistent negative cash flows impacting financial flexibility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	11.10M	15.82M	13.20M	9.16M	3.99M	0.00
Gross Profit	4.36M	6.42M	6.90M	7.07M	3.25M	-6.60M
EBITDA	-34.98M	-32.93M	-64.76M	-28.22M	-24.41M	-5.70M
Net Income	-39.48M	-38.43M	-70.58M	-35.89M	-32.57M	-13.09M
Balance Sheet
Total Assets	55.05M	87.50M	97.29M	113.00M	143.54M	25.78M
Cash, Cash Equivalents and Short-Term Investments	48.74M	39.26M	75.70M	90.89M	117.94M	10.65M
Total Debt	1.45M	5.64M	3.78M	6.95M	8.18M	12.45M
Total Liabilities	10.26M	23.02M	28.07M	16.68M	19.34M	26.78M
Stockholders Equity	44.80M	64.47M	69.22M	96.32M	124.20M	-1.00M
Cash Flow
Free Cash Flow	2.14M	-32.06M	-55.21M	-23.84M	-33.59M	-807.00K
Operating Cash Flow	-1.77M	-31.64M	-52.20M	-22.95M	-28.47M	-595.00K
Investing Cash Flow	-29.95M	273.00K	19.93M	-17.63M	-5.11M	-212.00K
Financing Cash Flow	-9.61M	-4.84M	36.94M	-6.33M	140.88M	-881.00K

Captor Therapeutics SA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 38.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PL:CTX, the sentiment is Negative. The current price of 38 is above the 20-day moving average (MA) of 37.23, below the 50-day MA of 39.59, and below the 200-day MA of 39.87, indicating a neutral trend. The MACD of 0.08 indicates Negative momentum. The RSI at 48.56 is Neutral, neither overbought nor oversold. The STOCH value of 48.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PL:CTX.

Captor Therapeutics SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SLV	59 Neutral	zł679.15M	1,434.11	―	―	14.10%	-99.00%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CTX	44 Neutral	€215.07M	―	-83.02%	―	-40.45%	27.53%
RVU	38 Underperform	€649.68M	―	-80.59%	―	15.45%	-25.81%